Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 31, 2025PharmaceuticsOpen Access

Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumor After Imatinib Resistance

View Full Paper
Ask AI
Bookmark
Share

Authors

XXXianHao XiaoFirst Hospital of China Medical UniversityQZQian-Shi ZhangCentral South UniversityJHJing HuTianjin University of Traditional Chinese Medicine

Discussion

Loading...

Member takes

Implication

Review evaluates resistance mechanisms and subsequent tyrosine kinase inhibitors in GIST patients, suggesting precision medicine strategies.

Key Points

  • Gastrointestinal stromal tumors are commonly driven by mutations in KIT and PDGFRA, contributing to treatment challenges.
  • Imatinib has revolutionized GIST treatment but resistance necessitates the evaluation of additional tyrosine kinase inhibitors.
  • Approved second- and third-line therapies like sunitinib and regorafenib target specific mutational profiles in resistant cases.
  • Future approaches, including precision medicine and ctDNA-guided therapy, aim to improve outcomes in GIST treatment.

Cite This Study

Xiao et al. (2025) studied this question.

synapsesocial.com/papers/689a0c5fe6551bb0af8cf6e4https://doi.org/10.3390/pharmaceutics17070923
View Full Paper
Ask AI
Bookmark
Share